Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Gives Samsung Bioepis A Further Ranibizumab Approval

Health Canada Nod For Byooviz Lucentis Rival Follows US And EU

Executive Summary

Samsung Bioepis has racked up a further endorsement for its Byooviz biosimilar ranibizumab, after Health Canada approved the rival to Lucentis.

You may also be interested in...



Supply Security And Competitive Pricing Will Support Byooviz Launch In US

In the first part of an exclusive two-part interview, Samsung Bioepis’ development division leader Kyung-Ah Kim and Biogen’s global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.

Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US

Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel